Cagrilintide and CagriSema: the amylin analog explained
Research & educational use only. This content is not medical advice. Consult a qualified healthcare professional before using any peptide compound.
Cagrilintide is worth understanding because it is a different mechanism from the GLP-1 drugs: a long-acting amylin analog acting on amylin and calcitonin receptors to promote satiety. The CagriSema program studies it combined with semaglutide.
Phase 2 data support meaningful weight reduction and phase 3 is ongoing, so it is investigational, not approved. It is a good example of how the obesity pipeline is moving beyond single-pathway incretin drugs.
3